Jefferson scientists find Cox-2 may play role in some brain tumors

May 21, 2002

Oncologists at Jefferson Medical College have shown for the first time in two separate studies that the enzyme cyclooxygenase-2 (COX-2), which is the target for the popular anti-arthritis drugs - and COX-2 inhibitors - Celebrex and Vioxx, is actually "overexpressed" in two types of common brain tumors.

While it's too early to say what role, if any, COX-2 may play in these brain tumors, the researchers say the findings open up the possibility of future human trials examining the effectiveness of drugs to block the enzyme's activity in treating the diseases.

According to Adam Dicker, M.D., Ph.D., associate professor of radiation oncology and director of the Division of Experimental Radiation at Jefferson Medical College of Thomas Jefferson University in Philadelphia, there are no effective drugs to treat meningioma, one of the most common brain tumors (3 to 6 cases per 100,000 persons), and pituitary tumors known as pituitary macroadenomas. Surgery and radiation are somewhat effective, but both diseases frequently return after treatment. Few molecular targets for drugs for these diseases are known. Dr. Dicker wondered if COX-2, which is known to be in higher-than-usual amounts in some tumors, was present in an "up-regulated" or extremely active state in these types of tumors and might potentially be such a drug target. COX-2 is also known to enhance the effects of radiation and chemotherapy on some tumors.

Dr. Dicker notes that the tumors are very different. Meningiomas can grow to large sizes and cause various symptoms, whereas pituitary tumors are benign and more likely to cause hormonal imbalances in the body, and in some cases, visual problems.

In one study, Dr. Dicker, Lawrence Kenyon, M.D., Ph.D., assistant professor of pathology, anatomy and cell biology at Jefferson Medical College and their co-workers examined tumor samples from 83 patients with meningioma. They found that COX-2 expression is higher than normal in the tumors, and what's more, the greater the amount of enzyme present, the more aggressive the disease. "This is the first time anyone has looked at meningiomas and found this correlation of progression of disease," Dr. Dicker says. In a second study, Drs. Dicker and Kenyon and their colleagues examined 35 samples from patients with benign macroadenomas. They also found that the tumors overexpressed COX-2. Pituitary tumors with high levels of COX-2 also showed high levels of thyroid-stimulating hormone, which plays a role in hyperthyroidism. The results of both studies will be presented separately on May 21 at the annual meeting of the American Society of Clinical Oncology in Orlando. Dr. Dicker believes these findings may represent new opportunities for designing potential therapies for brain tumors. He says future clinical studies will look at the effectiveness of COX-2 inhibitors alone or in combination with radiation therapy on these types of brain tumors. Dr. Dicker will be involved in a trial currently being planned by the Radiation Therapy Oncology Group, a federally funded cancer clinical trials group that carries out multi-disciplinary oncology research nationwide, looking at COX-2 and other targeted therapies against meningioma.
-end-
Editors: This information is embargoed for release May 21 at 12 p.m. at the annual meeting of the American Society of Clinical Oncology in Orlando. (Abstract nos. 294 and 296)

Thomas Jefferson University

Related Radiation Therapy Articles from Brightsurf:

Pulmonary artery thrombosis a complication of radiation therapy
According to ARRS' American Journal of Roentgenology, the imaging findings of in situ pulmonary artery thrombosis (PAT) associated with radiation therapy (RT) are different from those of acute pulmonary emboli and do not appear to embolize.

New approach for calculating radiation dosimetry allows for individualized therapy
Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan.

Developing microbeam radiation therapy (MRT) for inoperable cancer
An innovative radiation treatment that could one day be a valuable addition to conventional radiation therapy for inoperable brain and spinal tumors is a step closer, thanks to new research led by University of Saskatchewan (USask) researchers at the Canadian Light Source (CLS).

Travel considerations specified for 177Lu-DOTATATE radiation therapy patients
Researchers and patient advocates have addressed the challenges related to traveling after receiving 177Lu-DOTATATE radiation therapy in a study published in the April issue of The Journal of Nuclear Medicine.

A new way to monitor cancer radiation therapy doses
More than half of all cancer patients undergo radiation therapy and the dose is critical.

AI can jump-start radiation therapy for cancer patients
Artificial intelligence can help cancer patients start their radiation therapy sooner -- and thereby decrease the odds of the cancer spreading -- by instantly translating complex clinical data into an optimal plan of attack.

Towards safer, more effective cancer radiation therapy using X-rays and nanoparticles
X-rays could be tuned to deliver a more effective punch that destroys cancer cells and not harm the body.

Radiation therapy effective against deadly heart rhythm
A single high dose of radiation aimed at the heart significantly reduces episodes of a potentially deadly rapid heart rhythm, according to results of a phase one/two study at Washington University School of Medicine in St.

New mathematical model can improve radiation therapy of brain tumours
Researchers have developed a new model to optimize radiation therapy and significantly increase the number of tumor cells killed during treatment.

Using artificial intelligence to deliver personalized radiation therapy
New Cleveland Clinic-led research shows that artificial intelligence (AI) can use medical scans and health records to personalize the dose of radiation therapy used to treat cancer patients.

Read More: Radiation Therapy News and Radiation Therapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.